Paras Biopharmaceuticals Finland Oy is committed to innovation and high quality products and technology. Paras Biopharmaceuticals Finland Oy has developed robust biosimilars technologies for the following products.
Category |
Product/ Biosimilars Technology |
Technology Platform |
Osteoporosis | PB Osteo-1010 (Biosimilar) | Diabrid Technology / NobleCleav® Technology |
Rheumatoid Arthritis | PB (RA)- 2010 ( Biosimilar) | High Expression Technology |
Metabolic Disorders | PB (MDT)- 3010 (Biosimilar) | Diabrid Technology / NobleCleav® Technology |
Metabolic Disorders | PB (MDT)- 3020 ( Biosimilar) | Diabrid Technology / NobleCleav® Technology |
Metabolic Disorders | PB (MDT)- 3030 ( Biosimilar) | High Expression Technology |
Metabolic Disorders | PB (MDT)- 3040 ( Biosimilar) | Diabrid Technology / NobleCleav® Technology |
Oncology | PPB (CT)- 4010 | Under Development |
Oncology | PB (CT)- 4020 | Under Development |
Products under patents are part of our research projects. These products may be offered only in those countries where patents have expired.
For the latest status, please contact Paras Biopharmaceuticals Finland Oy.
Paras Biopharmaceuticals
Finland Oy,
Kiviharjunlenkki 10, OULU,
FI-90220 Finland
P: +358 442709462
Dr Ashesh Kumar
E: kumar.ashesh@parasbiopharma.com
P: +358 (0) 400207380
Dr Upendra Khurana
E: upendra.khurana@parasbiopharma.com
P:+358 (0) 449783160
Dr Mark Jackson
E: mark.jackson@parasbiopharma.com
P:+358 (0) 442905993
Skype: Paras.Finland